A61K 2039/64
Medicinal preparations containing antigens or antibodies: characterised by the architecture of the
Official title: {characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units}
A61K2039/64 (Medicinal preparations containing antigens or antibodies: characterised by the architecture of the) appears on 373 US grants and 669 published applications in this corpus.
Search patents in A61K- Granted patents
- 373
- Published applications
- 669
- Assignees
- 373
- Inventors
- 1,312
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 3 | 0 |
| 1998 | 4 | 0 |
| 1999 | 5 | 0 |
| 2000 | 2 | 0 |
| 2001 | 4 | 2 |
| 2002 | 3 | 5 |
| 2003 | 4 | 9 |
| 2004 | 3 | 14 |
| 2005 | 1 | 14 |
| 2006 | 10 | 20 |
| 2007 | 3 | 18 |
| 2008 | 5 | 12 |
| 2009 | 14 | 17 |
| 2010 | 9 | 25 |
| 2011 | 6 | 29 |
| 2012 | 7 | 18 |
| 2013 | 9 | 14 |
| 2014 | 19 | 25 |
| 2015 | 17 | 39 |
| 2016 | 18 | 33 |
| 2017 | 23 | 32 |
| 2018 | 24 | 46 |
| 2019 | 22 | 42 |
| 2020 | 26 | 30 |
| 2021 | 23 | 34 |
| 2022 | 21 | 34 |
| 2023 | 19 | 39 |
| 2024 | 25 | 47 |
| 2025 | 25 | 39 |
| 2026 | 13 | 32 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Therapeutic anticancer neoepitope vaccine4 Aug 2026US 12,697,377 B2Nykode Therapeutics ASA
- Modified envelope protein of human immunodeficiency virus and use thereof4 Aug 2026US 12,697,383 B2Xiamen Innovax Biotech Co., Ltd.
- Multiple antigenic peptide against corona virus and immunostimulating composition containing the same4 Aug 2026US 12,697,384 B2Animal Allergy Clinical Laboratories Inc.
- Multiepitope vaccine for the treatment of ALZHEIMER'S disease23 Jun 2026US 12,661,392 B2Othair Prothena Limited
- Unified platform for rapid production of nanovaccines with enhanced safety, efficacy and precision9 Jun 2026US 12,651,648 B2Santa Clara University
- Rhizavidin variants8 Oct 2026US 2026/0308208 A1Affinivax, Inc.
- Biodegradable scaffolds for enhancing vaccine efficacy24 Sep 2026US 2026/0284184 A1The Regents of the University of California
- Antigenic Multimeric Respiratory Syncytial Virus Polypeptides10 Sep 2026US 2026/0265309 A1Sanofi
- Modified biotin-binding protein, fusion proteins thereof and applications10 Sep 2026US 2026/0265313 A1Children's Medical Center Corporation
- Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response27 Aug 2026US 2026/0248912 A1Barinthus Biotherapeutics North America, Inc.
Most cited
By later US patents
- Conformationally-restricted combinatiorial library composition and method117US 5,824,483 APence, Inc. · 1998
- Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen109US 9,669,089 B2CureVac AG · 2017
- Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof74US 5,580,563 A1996
- Antigenic modification of polypeptides56US 4,526,716 AThe Ohio State University · 1985
- Antigenic modification of polypeptides55US 4,691,006 AThe Ohio State University · 1987